Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SpringWorks Therapeutics, Inc.SWTX · Entity 15910 | 10% owner | August 10, 2021 | August 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SpringWorks Therapeutics, Inc.
Report date August 10, 2021 · Filed August 13, 2021
Jointly reported with Bain Capital Life Sciences Investors, LLC, Schwartz Jeffrey Lawrence, Koppel Adam
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,831,307 |
Reported balance
After 2021-08-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-08-10 · Sale · Disposed 1,000,000 · Balance 4,831,307 F1: Represents shares of common stock held directly by BC SW, LP. F2: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein. F3: Jeffrey Schwartz is a director of the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 1,106 |
Reported balance
Holding disclosure · report date 2021-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,106 F4: Represents a restricted stock award held directly by Jeffrey Schwartz. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock held directly by BC SW, LP.
F2: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.
F3: Jeffrey Schwartz is a director of the Issuer.
F4: Represents a restricted stock award held directly by Jeffrey Schwartz.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2021 Filed Aug 13, 2021 00:38 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 1,000,000 | $70.25 | $70,250,000.00 |
DisclosureSEC source: 0000899243-21-032893 · doc4.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,831,307 F1 · ownership.nature: Represents shares of common stock held directly by BC SW, LP. F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein. F3 · ownership.nature: Jeffrey Schwartz is a director of the Issuer. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 21:30 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 1,450,000 | $71.50 | $103,675,000.00 |
DisclosureSEC source: 0000899243-21-011153 · doc4.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,831,307 F1 · ownership.nature: Represents shares of common stock held directly by BC SW, LP. F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Mr. Schwartz is a director of the Issuer. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 23:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,053,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023936 · doc4.xml · derivative · entry 5 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,053,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date. F2 · price: Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date. F4 · ownership.nature: Represents shares held directly by BC SW, L.P. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F6 · ownership.nature: Jeffrey Schwartz is a director of the Issuer. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 23:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | ConversionSeries A Convertible Preferred Stock · Derivative | 6,078,103 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023936 · doc4.xml · derivative · entry 4 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 6,078,103 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date. F4 · ownership.nature: Represents shares held directly by BC SW, L.P. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F6 · ownership.nature: Jeffrey Schwartz is a director of the Issuer. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 23:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | PurchaseCommon Stock | 150,000 | $18.00 | $2,700,000.00 |
DisclosureSEC source: 0000899243-19-023936 · doc4.xml · nonDerivative · entry 3 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,281,307 F3 · shares: Represents shares purchased in the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by BC SW, L.P. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F6 · ownership.nature: Jeffrey Schwartz is a director of the Issuer. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 23:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | ConversionCommon Stock | 1,053,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023936 · doc4.xml · nonDerivative · entry 2 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,131,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date. F4 · ownership.nature: Represents shares held directly by BC SW, L.P. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F6 · ownership.nature: Jeffrey Schwartz is a director of the Issuer. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 23:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | ConversionCommon Stock | 6,078,103 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023936 · doc4.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BC SW, LP · CIK 0001786351 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,078,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date. F4 · ownership.nature: Represents shares held directly by BC SW, L.P. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F6 · ownership.nature: Jeffrey Schwartz is a director of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.